Harrow’s branded eye-care portfolio is scaling rapidly, but the upside from VEVYE and G-MELT must overcome heavy debt service, integration costs, and execution risk.
Overview
Harrow is a specialty pharmaceutical company focused on ophthalmic disease management, with branded FDA-approved medicines and a smaller customized-compounding business. Its strategic shift from compounding toward branded products is evident in Q3 2026, when branded sales were $83.5 million, approximately 84% of revenue, and total revenue reached $99.3 million, up 38.7% year over year. VEVYE led growth at $39.7 million, up 75%; IHEEZO contributed $25.3 million and TRIESENCE a record $10.7 million. **The commercial thesis is that differentiated products, expanding payor coverage, and Harrow’s practitioner channel can sustain growth and improve margins.** TYRVAYA adds an expected $30 million-plus of 2027 revenue, while G-MELT could launch in 2028 after a planned H1 2027 NDA. The near-term financial picture is less clean: management cut 2026 Adjusted EBITDA guidance from $80–$100 million to more than $40 million, though it expects more than $33 million in Q4. At roughly $28 per share, the stock is near its 52-week low; valuation is about 3.5x forward sales and 15.7x 2027 normalized earnings. **Debt and cash-flow execution are the key constraints on an otherwise substantial growth opportunity.**